1. TRIANGLE. Autologous Transplantation after rituximab/Ibrutinib/Ara-c containig induction generalized mantle cell lymphoma- a randomized European mcl network trial
    Primary researcher: Sirpa Leppä

  2. A phase 2, single-arm, multi-cohort, multi-center trial to determine the efficacy and safety of JCAR017 in adult subjects with aggressive B-cell Non-Hodgkin lymphoma
    Primary researcher: Sirpa Leppä

  3. Biomarker driven and dose intensified chemoimmunotherapy with early CNS prophylaxis in patients less than 65 years with high risk diffuse large B-cell lymphpoma
    The goal of the study is to develop a combination therapy as effective and tolerable as possible for patients with fast-growing B-cell lymphoma that has a high risk of recurrence.  The study assess whether treatment results can be improved by taking into account the biological factors related to the cancer tissue resulting in a poor prognosis when implementing cytostatic therapy. The drugs administered in the study are either the traditional R-CHOEP therapy or the new etoposide-prednisone-vincristine-cyclophosphamide-doxorubicin (R-EPOCH) trial drug therapy.
    Primary researcher: Sirpa Leppä

  4. Brentuxumab vedotin or B-CAP in treatment of older patients with newly diagnosed classical Hodgkin Lymphoma - a GHSG-NLG Intergroup Phase II- trial
    The purpose of the study is to assess whether treatment results for patients over the age of 60 can be improved by including brentuximab vedotin (ADCETRIS®) in the therapy in its early stages. The trial drug, brentuximab vedotin, is made of a combination of an antibody and a drug that destroys cancer cells.

    The study also aims to assess if the combined cytostatic therapy used here has a positive effect on the overall effectiveness of the therapy, and if the combination causes less adverse effects than the traditional therapy.

    The cytostatic therapy used in the study is a modified CHOP combination where the vinca alcaloid, vincristine has been replaced with brentuximab vedotin. The new combination is called B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin, prednisone).
    Primary researcher: Sirpa Leppä

  5. A phase 1/2 study of combination of pixantrone, etoposide, bendamustine and in CD-20 positive tumors, rituximab in patients with relapsed aggressive non-Hodgkin lymphomas of B- or T- cell phenotype- The PREBEN study
    The purpose of the study is to assess the benefits of combining the new cytostatic drug, pixantrone (P), with two known cytostatic drugs, etoposid (E) and bendamustin (B). Patients with B-cell lymphoma whose cancer cells contain the protein CD20 on their surface will additionally receive an antibody called rituximab (R). The trial compound’s name, P(R)EBEN, is formed by taking the initials of the drugs used.
    Primary researcher: Sirpa Leppä

  6. A phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin's lymphoma (iNHL)- CHRonos-4
    The purpose of the this study is to assess the safety and effectiveness of copanlisib when combined with traditional immunochemotherapy, and to examine which copanlisib dose (45 mg or 60 mg) can be safely administered in combination with the immunochemotherapy used in the study to avoid excessive side effects. For the purpose of this study, immunochemotherapy means combinations of the drug rituximab and other cancer drugs. The immunochemotherapies used in this study are R B (rituximab + bendamustine) and R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, and prednisone).
    Primary researcher: Sirpa Leppä

 Contact Information
tel. +358 50 427 0680